Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.
Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs
Christopher Shenoy
Mucosal immunopathology encompasses a broad spectrum of diseases and conditions affecting mucosal surfaces throughout the body. This abstract provides an overview of the multifaceted aspects of mucosal immunopathology, emphasizing the underlying mechanisms, diagnostic challenges, and therapeutic approaches. Mucosal surfaces, including the respiratory, gastrointestinal, and genitourinary tracts, serve as critical interfaces between the external environment and the host. Consequently, they are particularly susceptible to various pathogens, allergens, and autoimmune processes, which can lead to immune dysregulation and tissue damage. Understanding the intricate balance between host defense and pathological responses in mucosal tissues is pivotal in managing a wide range of conditions, such as inflammatory bowel disease, allergic rhinitis, and infectious diseases like HIV and COVID-19. The pathogenesis of mucosal immunopathology involves intricate interactions between immune cells, epithelial barriers, and resident microbiota. Dysregulation of the immune response, including overactivation or insufficient control, plays a central role in many mucosal diseases. These imbalances can result in chronic inflammation, tissue damage, and ultimately impact the patient’s quality of life. Diagnosing mucosal immunopathology often presents challenges due to the overlapping clinical presentations and the need for invasive procedures. Innovative diagnostic tools, including advanced imaging techniques, molecular assays, and biomarker identification, have improved our ability to identify and characterize these conditions more accurately. Therapeutic strategies for mucosal immunopathology vary depending on the specific disease but may include immunosuppressive agents, biologics, and targeted therapies. A better understanding of the molecular pathways and immunological processes involved has led to the development of more effective and personalized treatment approaches.